DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is principally engaged in the business activity of developing treatments for unmet clinical needs or where no therapies are available with a primary focus on chronic kidney disease and acute ischemicstroke. Its pip... DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is principally engaged in the business activity of developing treatments for unmet clinical needs or where no therapies are available with a primary focus on chronic kidney disease and acute ischemicstroke. Its pipeline product DM199 is a recombinant form of human tissue kallikrein-1. Show more
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic disease, today announced the closing of its...
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, today announced that it has entered...
Preeclampsia Program to be Initiated with a Phase 2 Investigator-sponsored Trial Beginning in Q4 2024 Key Proof-of-Concept Results Expected in the First Half of 2025 Management will Host a...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.2 | -4.71698113208 | 4.24 | 4.95 | 3.9836 | 78357 | 4.34605932 | CS |
4 | 0.06 | 1.50753768844 | 3.98 | 4.95 | 3.76 | 54433 | 4.19916414 | CS |
12 | 0.95 | 30.7443365696 | 3.09 | 4.95 | 2.65 | 55062 | 3.62700849 | CS |
26 | 1.18 | 41.2587412587 | 2.86 | 4.95 | 2.14 | 54555 | 3.22547355 | CS |
52 | 1.03 | 34.219269103 | 3.01 | 4.95 | 1.9382 | 51096 | 2.95832292 | CS |
156 | 0.02 | 0.497512437811 | 4.02 | 4.95 | 1.12 | 82312 | 2.83162579 | CS |
260 | 1.26 | 45.3237410072 | 2.78 | 10.88 | 1.12 | 98758 | 4.34822434 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.